Amgen sweeps last BCMA BiTE standing out of pipeline
Exactly a year after resuming dosing on a bispecific that hits BCMA, Amgen is scrapping the drug altogether for “strategic reasons.”
The move — along with a separate decision to deprioritize acapatamab in favor of another PSMA-targeting drug, AMG 340, for the treatment of metastatic castrate-resistant prostate cancer — marks another round of trial and error as Amgen figures out the best configurations and uses of its half-life extended bispecific T cell engagers (BiTEs).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.